Pharmaceuticals
-
Vaccine variations pass tests
Delaying second vaccine doses for months and mixing different types of COVID-19 vaccine all seem to be effective, according to findings reported by British researchers. Read more
-
Booster vaccine targets rogue variant
The first vaccine specifically tailored to tackle a new variant of COVID-19 is now being tested on volunteers, it was announced last night. Read more
-
Statins for heart failure linked to fewer cancers
People with heart failure who take statins may be at a reduced risk of cancer, researchers say today. Read more
-
Test may protect bladder cancer patients from relapse
Researchers looking at a new biomarker of residual bladder cancer have found that it identifies high risk patients who may benefit from additional treatment. Read more
-
Promising new way to fight SARS-CoV-2 unveiled
A new treatment that mends cell damage, rather than fighting the SARS-CoV-2 virus, has been shown to be effective in lab models. Read more
-
New drug class for cancers with faulty BRCA genes
A new class of targeted cancer drugs could treat patients whose tumours have faulty copies of the BRCA cancer genes, British researchers have reported. Read more
-
Monoclonal antibody combination can save COVID-19 patients’ lives
An antibody combination reduces the number of deaths among patients hospitalised with severe COVID-19 when they are are unable to mount their own immune response, British researchers have announced. Read more
-
Cold virus may limit COVID-19
Viruses which cause the common cold may protect against COVID-19, new research suggests. Read more
-
Needle phobia partly explains vaccine refusal
People with needle phobia are twice as likely to delay or refuse a COVID-19 vaccine as others, British researchers report today. Read more
-
Could semaglutide protect people with type 2 diabetes?
A major new study will assess if a daily dose of semaglutide could help to prevent people with type 2 diabetes developing cardiovascular disease, it has been announced. Read more
